Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Assets (2016 - 2025)

Historic Return on Assets for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to 0.35%.

  • Lineage Cell Therapeutics' Return on Assets fell 1500.0% to 0.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year decrease of 1500.0%. This contributed to the annual value of 0.17% for FY2024, which is 200.0% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Return on Assets is 0.35%, which was down 1500.0% from 0.31% recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Return on Assets ranged from a high of 0.1% in Q3 2021 and a low of 0.36% during Q3 2022
  • Its 5-year average for Return on Assets is 0.23%, with a median of 0.21% in 2023.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Return on Assets skyrocketed by 2900bps in 2021 and then plummeted by -2600bps in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Return on Assets (Quarter) stood at 0.28% in 2021, then increased by 25bps to 0.21% in 2022, then fell by 0bps to 0.21% in 2023, then grew by 15bps to 0.18% in 2024, then tumbled by -100bps to 0.35% in 2025.
  • Its Return on Assets stands at 0.35% for Q3 2025, versus 0.31% for Q2 2025 and 0.16% for Q1 2025.